Ginkgo Bioworks
Ginkgo Bioworks: Engineering biology, designing custom organisms for diverse markets.
Competitive Advantages
Ginkgo Bioworks earns revenue by selling access to automated laboratory capacity and the biological data that capacity generates. Customers order experiments through Cloud Lab interfaces or commission Solutions partnerships, while Datapoints packages large experimental datasets as fee-for-service Lab Data as a Service products.
The Build Your Own Lab line extends the model to automation hardware, software, support, and applications that customers deploy in their own facilities. Reagents and ongoing service relationships add repeat commercial attach points around the core autonomous-lab infrastructure.
Source: ginkgo.bio
Memo
Ginkgo Bioworks is an operating public company listed on the New York Stock Exchange under the ticker DNA. The company continues to run autonomous laboratories, Cloud Lab services, and Datapoints data products for cell-programming customers.
Recent reporting covers quarterly financial results alongside partnership extensions and collaborations in agricultural biologicals and precision biologics. Biosecurity operations were divested in 2026 as the company concentrated on its autonomous-lab platform.
Source: investors.ginkgobioworks.com
Product Overview
Ginkgo Bioworks offers a cell-programming platform built on Build Your Own Lab automation, hardware, software, support, and applications that customers can deploy themselves. Cloud Lab provides remote access to robotic experiment execution ordered through software interfaces.
Solutions partnerships pair that infrastructure with strain engineering and machine learning for markets including agricultural biologicals. Datapoints data products and Reagents round out the portfolio for customers building on Ginkgo-generated biological data.
Source: ginkgo.bio